Fears U.S. President Donald Trump could damage the drugs industry have not been realized and the administration’s efforts to accelerate new medicine approvals will bolster the sector, the chairman of Swiss drugmaker Roche said.
“The U.S. Food and Drug Administration (FDA) wants to trim the time it takes for drugs to be approved,” Christoph Franz told Swiss newspaper Blick in an interview published on Friday.
“European regulators, when it comes to approving new medicines, are lagging the Americans by around six to 12 months. Europe has some catching up to do.”
FDA Commissioner Scott Gottlieb, whom Trump brought in, aims to approve drugs based on very early data if they show a possible survival benefit, among other measures to get medicines on the market faster.
After he was elected, Trump blasted drug companies, saying they had been “getting away with murder” with high prices.
While the Trump administration has since sought to change how hospitals are reimbursed for some drugs, his selection of Gottlieb, with deep ties to the drug industry, eased worries that he would seek a confrontation.
“Fears that Trump would damage the pharmaceuticals branch have not been realized,” Franz, who was in Davos for the World Economic Forum meeting, told Blick in the interview.
“It’s quite the opposite. We see new opportunities.”
By John Miller
Source: Reuters
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
